| 000 | 01175 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250514043658.0 | ||
| 264 | 0 | _c20021119 | |
| 008 | 200211s 0 0 jpn d | ||
| 022 | _a0022-9776 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTomioka, Haruaki | |
| 245 | 0 | 0 |
_a[Prospects for development of new antituberculous drugs]. _h[electronic resource] |
| 260 |
_bKekkaku : [Tuberculosis] _cAug 2002 |
||
| 300 |
_a573-84 p. _bdigital |
||
| 500 | _aPublication Type: Lecture | ||
| 650 | 0 | 4 | _a4-Quinolones |
| 650 | 0 | 4 | _aAdjuvants, Immunologic |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aAnti-Bacterial Agents |
| 650 | 0 | 4 | _aAnti-Infective Agents |
| 650 | 0 | 4 |
_aAntitubercular Agents _xpharmacology |
| 650 | 0 | 4 | _aDrug Delivery Systems |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 | _aDrug Resistance, Bacterial |
| 650 | 0 | 4 | _aForecasting |
| 650 | 0 | 4 | _aGene Targeting |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMacrolides |
| 650 | 0 | 4 |
_aMycobacterium avium Complex _xdrug effects |
| 650 | 0 | 4 |
_aMycobacterium tuberculosis _xdrug effects |
| 650 | 0 | 4 | _aRifamycins |
| 773 | 0 |
_tKekkaku : [Tuberculosis] _gvol. 77 _gno. 8 _gp. 573-84 |
|
| 999 |
_c12115014 _d12115014 |
||